Medifast 3Q 2026: Revenue $72.05M, Net income ($17.51M), EPS ($1.57) — 10-Q Summary

What happened

Medifast reported third-quarter 2026 revenue of $72.05 million, down 19.4% from a year earlier, and a net loss of $17.51 million. Diluted loss per share was $1.57, versus $0.21 previously. Active earning coaches fell to 10,200 from 19,500.

Confirmed

Global impact / market context

The company's sales force, which means the coaches who bring in customers, nearly halved while the net loss widened sharply. That signals fewer people selling Medifast products, so future revenue may stay under pressure even though revenue per coach rose 54.1% to $7,064.

Analyst inference

Medifast is shifting away from its OPTAVIA program toward a broader science-backed metabolic health market and launched Trilivy in July. It also introduced a new compensation plan and a coach support hub, aiming to rebuild the selling network while cutting costs under Project Catalyst.

Analyst inference

What to watch

1. Management expects active earning coach numbers to continue declining through 2026, so watch whether that decline slows before the company can stabilize revenue. Confirmed
2. Project Catalyst changes facilities, technology and workforce to accelerate profitability while preserving growth capabilities; watch whether those cost cuts lift profit without harming customer acquisition. Proposed
3. The new compensation plan and Trilivy Coach Hub are meant to recruit and support coaches; watch whether they reverse the coach decline, since coach count drives revenue. Analyst inference

Evidence

• Original source link unavailable